Related to Protalix, Pfizer Report FDA Approval of Plant-Derived Gaucher Disease ERT Elelyso

• FDA Clears MedImmune’s FluMist Quadrivalent Flu Vaccine
  
• FDA Clears Discovery Laboratories’ Drug for Respiratory Distress Syndrome in Infants
  
• FDA Approves Organogenesis’ Gintuit Cell-Based Product for Gum Disease
  
• Pfizer, Biocon End Insulin Biosimilars Partnership
  
• FDA Clears Affymax and Takeda’s Once-Monthly ESA for Anemic CKD Patients on Dialysis
  
• Synageva, Mitsubishi Tanabe Pharma Add Second Rare Disease Program to Alliance
  
• 2-to-1 Majority of Respondents to a GEN Poll See Smooth Sailing Ahead for Vivus' Obesity Therapy
  
• FDA Clears Avid’s Amyloid Plaque Imaging Agent for Aiding Alzheimer Disease Diagnosis
  
• FDA Clears Qiagen’s Rotor-Gene MDx RT-PCR IVD Platform and Influenza Assay
  
• FDA Clears Leica’s Her2 Immunohistochemical Assay on Bond-Max Instrument
  
• Takeda’s Type 2 Diabetes Therapies Set Back Again by FDA
  
• FDA Requests More Risk-Benefit Data for Amgen’s Xgeva sBLA in Prostate Cancer
  
• Novartis’ Afinitor Gets FDA Okay for Treating Renal Angiomyolipoma Associated with TSC
  
• GSK’s Votrient Approved in U.S. for Treating Soft Tissue Sarcoma
  
• FDA Clears Novo Nordisk’s Levemir for Diabetic Children Aged Two Years and Over
  
• FDA Approves XenoPort, GSK’s Horizant for Managing Postherpetic Neuralgia
  
• FDA Clears Roche’s Perjeta as Combination Therapy for Metastatic Breast Cancer
  
• FDA Clears Immunetics' Rapid Test for Bacterial Contamination of Platelet Units
  
• FDA Approves GSK’s MenHibrix Meningitis Vaccine
  
• FDA Fails to Back Janssen, Bayer’s Xarelto for Acute Coronary Syndrome